EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, KPTI: Karyopharm Therapeut

06 Nov 26 15:59
LAST:

0.0483

CHANGE:
 0.01		OPEN:
0.0590		HIGH:
0.0980		ASK:
13.0800		VOLUME:
85.42M
CHG(%):
19.63		PREV:
0.0601		LOW:
0.0401		BID:
8.5100		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
06 Nov 260.05900.09800.04010.048385.42M
05 Nov 260.05390.06430.05010.060118.85M
04 Nov 260.08100.12740.07290.072940.92M
03 Nov 260.11000.11000.08200.088316.87M
02 Nov 260.15300.16000.09460.112047.45M
30 Oct 260.90200.90200.58420.66203.52M
29 Oct 260.80970.98690.78070.87986.85M
28 Oct 260.45600.90910.45600.832155.29M
27 Oct 260.45920.48290.43050.4800996.6K
26 Oct 260.50840.51660.42240.48211.37M

PROFILE

Name:Karyopharm Therapeut
About:Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Sector:Healthcare
Industry:Biotechnology
Address:85 Wells Avenue, Newton, MA, United States, 02459-3298
Website:https://www.karyopharm.com
CUSIP:48576U106
CIK:0001503802
ISIN:US48576U2050
FIGI:BBG001J272L7

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-0.64 
Forward P/E:-0.28 
PEG Ratio:0.00 
Price to Sales:0.67 
Price to Book:-0.06 
Profit Margin:-0.90 
Operating Margin:-0.64 
Return on Assets:-0.45 
Return on Equity:0.41 
EPS Ratio:-14.33 
Revenue:137.27M 
Shares:22.68M 
Market Cap:1.1M 

TECHNICAL INDICATORS

MA5:0.0858.0%
MA10:0.37669.8%
MA20:0.39717.6%
MA50:1.042,046.8%
MA100:3.607,359.0%
MA200:5.8812,069.4%
RSI14:40.06
WPR14:-100.00 
MTM14:-0.31
ROC14:-0.87 
ATR:0.16 
Week High:0.901,767.5%
Week Low:0.0420.4%
Month High:0.991,943.3%
Month Low:0.0412,069.4%
Year High:10.9922,653.6%
Year Low:0.0420.4%

RECENT SPLITS

Date Ratio
26 Feb 20251-15